Table 1.

Recommendations of systemic therapy from each guideline

Asia Guideline	Released year
	China 2019	Hong Kong 2021	Taiwan 2020	Japan 2021	Korea 2022
First-line	Atezolizumab+bevacizumab, sorafenib, lenvatinib, donafenib, sintilimab plus bevacizumab biosimilar, FOLFOX	Atezolizumab+bevacizumab, sorafenib, lenvatinib, nivolumab	Atezolizumab+bevacizumab, sorafenib, lenvatinib	Atezolizumab+bevacizumab, sorafenib, lenvatinib	Atezolizumab+bevacizumab, durvalumab+tremelimumab, lenvatinib, sorafenib
Second-line after sorafenib failure	Regorafenib, apatinib, camrelizumab, tislelizumab	Regorafenib, cabozantinib, ramucirumab, nivolumab +/-ipilimumab, pembrolizumab	Regorafenib, cabozantinib, ramucirumab, nivolumab +/- ipilimumab, pembrolizumab	Sorafenib, lenvatinib, regorafenib, ramucirumab, cabozantinib	Regorafenib, cabozantinib, ramucirumab, nivolumab+ipilimumab, pembrolizumab